Replies to post #177573 on Innovation Pharmaceuticals Inc (IPIX)

[Waverunner1]

If you are paying attention you know the current Kev trial is being conducted with input from (under the guidance of) a potential partner, ie, it was designed to provide data they deem important (and necessary) before moving forward in collaboration. I know you think you would be making better decisions but they are doing exactly what they should be doing.

They were pursuing a real survival study. Now they are going back to safety and moa. What is there to agree or disagree about? The company announces that the baby is going to walk, and then they realize it is not ready? They issue PR after PR over many months about the baby walking and then- sorry, back to a crawl.
Because they failed to demonstrate safety at more frequent doing? Or because they have no money for a real trial?

[frrol]

You'll just have to get over this. I think you still believe the company fumbled Kevetrin's PK analysis and was too ignorant (or negligent?) to alter the Phase 1 protocols, hence these "setbacks and delays", but I believe those were not the cases. Far more accurate I think is that we are progressing forward with Kevetrin as quickly as we can, and it is never quick enough.